Hugh Douglas Pulford

Title: The Innovations of Hugh Douglas Pulford

Introduction

Hugh Douglas Pulford is a notable inventor based in Wellington, New Zealand. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for diagnosing and treating nematode infections, showcasing the intersection of innovation and healthcare.

Latest Patents

Pulford holds a patent for an isolated monoclonal antibody known as mAb PAB-1. This antibody, deposited at the ATCC on January 24, 2002, and accorded accession PTA-4005, binds to a surface antigen on nematode L3. The patent also covers the antigen that interacts with the monoclonal antibody, as well as its applications in diagnosing, treating, or preventing nematode infections.

Career Highlights

Hugh Douglas Pulford is associated with Ovita Limited, a company that focuses on innovative solutions in the agricultural and veterinary sectors. His work at Ovita Limited has allowed him to apply his research in practical settings, contributing to advancements in the field.

Collaborations

Pulford has collaborated with notable colleagues such as Gavin Bernard Lear Harrison and Wayne Robert Hein. These partnerships have fostered a collaborative environment that enhances research and development efforts.

Conclusion

Hugh Douglas Pulford's contributions to biotechnology, particularly through his patent on monoclonal antibodies, highlight his role as an innovator in the field. His work continues to impact the diagnosis and treatment of nematode infections, demonstrating the importance of innovation in healthcare.